Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
Rhea-AI Summary
Tempest (Nasdaq: TPST) selected Cincinnati Children’s Applied Gene and Cell Therapy Center (AGCTC) to conduct technology transfer, development and IND‑enabling manufacturing for TPST-2003, a dual‑targeting CD19/BCMA CAR‑T for relapsed/refractory multiple myeloma.
As of a January 31, 2026 cutoff, 36 patients received TPST-2003; all six efficacy‑evaluable REDEEM-1 patients achieved complete response and overall response rate was 100% (25/25) among evaluable patients. Most activities are planned complete by Q3 2026 to support a potential IND filing in Q4 2026.
Positive
- 100% ORR among 25 evaluable patients (25/25)
- 100% CR in six efficacy‑evaluable REDEEM-1 patients
- AGCTC selected for tech transfer and IND‑enabling manufacturing
- Majority of non‑stability activities planned complete by Q3 2026
Negative
- Only 6 efficacy‑evaluable patients reported CRs in REDEEM-1
- Long‑term stability testing not complete and remains required before IND
- Planned IND timing is contingent on completion of remaining activities by Q3 2026
News Market Reaction – TPST
On the day this news was published, TPST declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
TPST was modestly higher by 0.42% while momentum scanners picked up two biotech peers (e.g., VRCA up 5.85%), but no broad, same-direction move across close peers was indicated.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 25 | Interim trial results | Positive | -6.4% | REDEEM-1 interim data for TPST-2003 with 100% ORR and all CRs. |
| Feb 11 | Strategy update | Positive | -3.7% | Strategic plan to advance newly acquired dual-targeting CAR-T programs. |
| Feb 04 | Asset acquisition | Positive | -6.3% | Closing of all-stock acquisition adding multiple CAR-T assets including TPST-2003. |
| Jan 20 | Warrant dividend | Positive | +1.2% | Announcement of record date for dividend distribution of stock purchase warrants. |
| Nov 25 | Equity offering | Negative | -23.3% | Registered direct stock sale and concurrent private placement of warrants. |
Recent positive clinical and strategic updates for TPST have often been met with negative price reactions, while dilutive financing and warrant events drew large, aligned selloffs.
Over the last few months, Tempest has shifted toward dual-targeting CAR-T assets like TPST-2003, closing an all-stock acquisition and outlining a capital-efficient development plan. Interim REDEEM-1 data showed a 100% overall response rate in evaluable patients, yet shares fell after these updates. A prior registered direct offering with warrants led to a sharp decline, while a warrant dividend saw a small gain. Today’s partnership for IND-enabling manufacturing fits this ongoing registrational push for TPST-2003 into 2026.
Market Pulse Summary
This announcement advances TPST-2003 by securing a specialized partner for tech transfer and IND-enabling manufacturing, targeting a potential IND filing in Q4 2026 and a planned U.S. registrational study in 2026. It builds on prior REDEEM-1 data showing a 100% ORR and 100% CR rate in key evaluable patients. Investors may watch for execution against the Q3 2026 manufacturing milestones, presentation of updated clinical data, and any future funding steps linked to this accelerated development plan.
Key Terms
ind-enabling regulatory
car-t medical
cd19 medical
bcma medical
overall response rate medical
complete response medical
extramedullary disease medical
AI-generated analysis. Not financial advice.
- Cincinnati Children’s Applied Gene and Cell Therapy Center selected to conduct tech transfer, development and IND-enabling manufacturing
- All activities other than long-term stability testing planned to be complete in Q3 2026 to support potential IND filing in Q4 2026
- Selection of tech transfer partner follows Tempest’s recent announcement of positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003, including
100% CR in all six efficacy evaluable patients, and accelerated development timeline
BRISBANE, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced the selection of Cincinnati Children’s Applied Gene and Cell Therapy Center (“AGCTC”) as the lead contract development and manufacturing partner to conduct the formal technology transfer of TPST-2003, Tempest’s dual-targeting CD19/BCMA CAR-T therapy under development for the treatment of relapsed/refractory multiple myeloma (“rrMM”).
Tempest recently announced that, as of a January 31, 2026 data cutoff, a total of 36 patients with rrMM had received one infusion of TPST-2003, including 24 patients in a prior Phase 1/2 investigator-initiated trial (IIT) and 12 patients in the ongoing REDEEM-1 trial, representing one of the largest datasets evaluating a CD19/BCMA dual-targeting CAR-T therapy. As of the data cutoff, all six efficacy evaluable patients enrolled in the REDEEM-1 trial had achieved a complete response (CR) according to the International Myeloma Working Group (IMWG) uniform response criteria. Among 25 evaluable patients with measurable disease at baseline across both studies, the overall response rate (“ORR”) was
“The recent positive results from the ongoing REDEEM-1 trial position TPST-2003 as a potential class-leading therapy for rrMM, which, subject to FDA approval, could offer a meaningful option for patients with rrMM,” said Dr. Matt Angel, President and Chief Executive Officer of Tempest. “The potential to treat patients with extramedullary disease (EMD) and patients who have previously received a BCMA-targeting CAR-T is particularly exciting. We are very pleased to have selected the AGCTC as our partner to execute the technology transfer of TPST-2003 as we prepare for our planned U.S. clinical development.”
The AGCTC is a research, development, and manufacturing hub advancing future cell and gene therapy (CGT) treatments for patients with unmet needs. Established in 2001, the center has evolved into a nationally recognized leader in CTG CDMO services with a proven track record that reflects Cincinnati Children’s commitment to solving unmet medical needs through translational science. AGCTC is part of the Cincinnati Children’s Cancer and Blood Diseases Institute, which is ranked #1 in the nation by U.S. News & World Report for pediatric cancer care.
“We are proud to have been selected to support the development of this exciting product candidate,” said Dr. Chaozhong Zou, Executive Director and General Manager of AGCTC, Cancer and Blood Diseases Institute, Cincinnati Children’s Hospital Medical Center. “The parallel-structure dual-targeting CAR architecture of TPST-2003 is truly innovative, and fits perfectly within our experience supporting technology transfer of engineered cell therapy products, including our extensive experience making novel CAR-T programs IND-ready. We look forward to generating the information needed to advance TPST-2003 to the next stage of development.”
About TPST-2003
TPST-2003 is an autologous CD19/BCMA dual-targeting CAR-T therapy designed to improve response depth and durability in patients with relapsed/refractory multiple myeloma (rrMM) through a parallel dual-targeting CAR structure designed to address tumor heterogeneity and antigen escape. TPST-2003 is being developed in China by Tempest’s partner, Novatim Immune Therapeutics (“Novatim”). Under its agreement with Novatim, Tempest has the exclusive right to develop TPST-2003 outside of China, India, Turkey, and Russia.
About REDEEM-1
REDEEM-1 (Study nos. CTR20233309/NCT06223646) is a Phase 1/2a clinical trial evaluating TPST-2003 in patients with relapsed/refractory multiple myeloma, including patients with high-risk cytogenetics and patients with extramedullary disease. The REDEEM-1 trial has a targeted full enrollment of 29 patients. The REDEEM-1 trial is sponsored and being conducted by Tempest’s partner, Novatim Immune Therapeutics, with a total of eight clinical sites registered in China: Peking Union Medical College Hospital (Dr. Jian Li; lead site), The First Affiliated Hospital of Nanchang University (Dr. Fei Li), Peking University First Hospital (Dr. Yujin Dong), Henan Cancer Hospital (Dr. Baijun Fang), Shanxi Provincial Cancer Hospital (Dr. Liping Su), The Second Xiangya Hospital of Central South University (Dr. Hongling Peng), The First Affiliated Hospital of China Medical University (Dr. Xiaojing Yan), and The Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College (Dr. Dehui Zou).
Additional clinical trials evaluating TPST-2003
A Phase 1/2 IIT (Study no. NCT04714827) is evaluating TPST-2003 in patients with relapsed/refractory multiple myeloma, including patients with high-risk cytogenetics and patients with extramedullary disease. The IIT is sponsored and being conducted by Tempest’s partner, Novatim Immune Therapeutics, with a total of two clinical sites registered in China: Shanghai Fourth People’s Hospital (Dr. Weijun Fu; lead site) and Shanxi Provincial Cancer Hospital (Dr. Liping Su).
A Phase 1 trial (Study nos. CTR20242409/NCT06518876) is evaluating TPST-2003 in patients with POEMS, a rare blood disorder caused by abnormal plasma cells. The Phase 1 trial is sponsored and being conducted by Tempest’s partner, Novatim Immune Therapeutics, with a total of three clinical sites registered in China: Peking Union Medical College Hospital (Dr. Jian Li; lead site), Xuanwu Hospital Capital Medical University (Dr. Wanling Sun), and West China Hospital, Sichuan University (Dr. Yu Wu).
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at https://www.tempesttx.com.
Forward-Looking Statements
This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (the “Securities Act”)) concerning Tempest Therapeutics, Inc. These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Tempest Therapeutics, as well as assumptions made by, and information currently available to, management of Tempest Therapeutics. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “could”, “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions. All statements that are not historical facts are forward-looking statements, including but not limited to, statements regarding: Tempest Therapeutics’ plan to present data from clinical trials, including the REDEEM-1 trial; the design, initiation, progress, timing, scope and results of clinical trials, including the anticipated initiation of U.S. registrational trial for TPST-2003 in Q4 2026; the planned advancement of a diversified next-generation CAR-T pipeline; anticipated therapeutic benefit and regulatory development of Tempest Therapeutics’ product candidates, including TPST-2003; and Tempest Therapeutics’ ability to achieve its operational plans. Any forward-looking statements in this press release are based on Tempest Therapeutics’ current expectations, estimates and projections about its industry as well as management’s current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to Tempest Therapeutics’ need for additional capital to fund its planned programs and operations and to continue to operate as a going concern; unexpected safety or efficacy data observed during preclinical or clinical trials; the possibility that results from prior clinical trials and preclinical studies may not necessarily be predictive of future results; past results may not be indicative of future results; clinical trial site activation or enrollment rates that are lower than expected; loss of key personnel; changes in expected or existing competition; changes in the regulatory environment; risks relating to volatility and uncertainty in the capital markets for biotechnology companies; and unexpected litigation or other disputes. These and other factors that may cause actual results to differ from those expressed or implied are discussed in greater detail in the “Risk Factors” section of Tempest’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the Securities and Exchange Commission (“SEC”) on November 5, 2025, and the “Risk Factors” section under Proposal 5 contained in Tempest’s definitive proxy statement on Schedule 14A, filed with the SEC on December 31, 2025, and in other documents filed by Tempest from time to time with the SEC. Except as required by applicable law, Tempest Therapeutics undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Tempest Therapeutics’ views as of any date subsequent to the date of this press release and should not be relied upon as prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Tempest Therapeutics.
Investor Contacts:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
FAQ
What did Tempest (TPST) announce about TPST-2003 on March 11, 2026?
What clinical results did Tempest report for TPST-2003 as of January 31, 2026?
How will the AGCTC partnership affect Tempest’s planned U.S. registrational study for TPST-2003?
What timeline did Tempest give for IND readiness for TPST-2003 (TPST)?
How many patients have received TPST-2003 and what studies contributed to that dataset?
